Renal Cancer Research Review, Issue 16

In this issue:

Therapies for metastatic clear cell RCC
Angiokines in patients with non-clear cell RCC
Biomarker for recurrence of localised RCC
Atezolizumab + bevacizumab for metastatic RCC
Active surveillance for young patients with small renal masses
Immune-related adverse events in metastatic RCC
Sex and age distribution of RCC metastases
Pembrolizumab as post-nephrectomy adjuvant therapy for RCC
Pembrolizumab + axitinib for advanced clear cell RCC
Telaglenastat + cabozantinib in advanced/metastatic RCC

Please login below to download this issue (PDF)